Literature DB >> 19297528

Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

Bénédicte Foveau1, Frédéric Ancot, Catherine Leroy, Annalisa Petrelli, Karina Reiss, Valérie Vingtdeux, Silvia Giordano, Véronique Fafeur, David Tulasne.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) acts through the membrane-anchored Met receptor tyrosine kinase to induce invasive growth. Deregulation of this signaling is associated with tumorigenesis and involves, in most cases, overexpression of the receptor. We demonstrate that Met is processed in epithelial cells by presenilin-dependent regulated intramembrane proteolysis (PS-RIP) independently of ligand stimulation. The proteolytic process involves sequential cleavage by metalloproteases and the gamma-secretase complex, leading to generation of labile fragments. In normal epithelial cells, although expression of cleavable Met by PS-RIP is down-regulated, uncleavable Met displayed membrane accumulation and induced ligand-independent motility and morphogenesis. Inversely, in transformed cells, the Met inhibitory antibody DN30 is able to promote Met PS-RIP, resulting in down-regulation of the receptor and inhibition of the Met-dependent invasive growth. This demonstrates the original involvement of a proteolytic process in degradation of the Met receptor implicated in negative regulation of invasive growth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297528      PMCID: PMC2675628          DOI: 10.1091/mbc.e08-09-0969

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  52 in total

1.  Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway.

Authors:  M Jeffers; G A Taylor; K M Weidner; S Omura; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

2.  Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells.

Authors:  M Ivan; J A Bond; M Prat; P M Comoglio; D Wynford-Thomas
Journal:  Oncogene       Date:  1997-05-22       Impact factor: 9.867

3.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

4.  Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells.

Authors:  K M Weidner; M Sachs; D Riethmacher; W Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons.

Authors:  F Maina; M C Hilton; C Ponzetto; A M Davies; R Klein
Journal:  Genes Dev       Date:  1997-12-15       Impact factor: 11.361

6.  Ets up-regulates MET transcription.

Authors:  G Gambarotta; C Boccaccio; S Giordano; M Andŏ; M C Stella; P M Comoglio
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

7.  Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form.

Authors:  A P Galvani; C Cristiani; P Carpinelli; A Landonio; F Bertolero
Journal:  Biochem Pharmacol       Date:  1995-09-28       Impact factor: 5.858

8.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.

Authors:  Y Uehara; O Minowa; C Mori; K Shiota; J Kuno; T Noda; N Kitamura
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

9.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.

Authors:  M F Di Renzo; M Olivero; A Giacomini; H Porte; E Chastre; L Mirossay; B Nordlinger; S Bretti; S Bottardi; S Giordano
Journal:  Clin Cancer Res       Date:  1995-02       Impact factor: 12.531

10.  In vivo effects of hepatocyte growth factor/scatter factor on mouse mammary gland development.

Authors:  J Yant; L Buluwela; B Niranjan; B Gusterson; T Kamalati
Journal:  Exp Cell Res       Date:  1998-06-15       Impact factor: 3.905

View more
  43 in total

Review 1.  The regulatory crosstalk between kinases and proteases in cancer.

Authors:  Carlos López-Otín; Tony Hunter
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

3.  Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels.

Authors:  Simone Buraschi; Nutan Pal; Nadia Tyler-Rubinstein; Rick T Owens; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

Review 4.  Receptor tyrosine kinases in the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-10-01       Impact factor: 10.005

5.  Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.

Authors:  Elisa Vigna; Giovanni Pacchiana; Cristina Chiriaco; Simona Cignetto; Lara Fontani; Paolo Michieli; Paolo M Comoglio
Journal:  J Mol Med (Berl)       Date:  2013-09-07       Impact factor: 4.599

6.  Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.

Authors:  Valentina Martin; Simona Corso; Paolo M Comoglio; Silvia Giordano
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

Review 7.  Current advances of targeting HGF/c-Met pathway in gastric cancer.

Authors:  Aristomenis Anestis; Ilianna Zoi; Michalis V Karamouzis
Journal:  Ann Transl Med       Date:  2018-06

8.  Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.

Authors:  Kyung Chan Park; Bekesho Geleta; Lionel Yi Wen Leck; Jasmina Paluncic; Shannon Chiang; Patric J Jansson; Zaklina Kovacevic; Des R Richardson
Journal:  J Biol Chem       Date:  2019-11-19       Impact factor: 5.157

9.  Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody.

Authors:  Giovanni Pacchiana; Cristina Chiriaco; Maria C Stella; Fiorella Petronzelli; Rita De Santis; Maria Galluzzo; Paolo Carminati; Paolo M Comoglio; Paolo Michieli; Elisa Vigna
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

10.  ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling.

Authors:  Miles A Miller; Aaron S Meyer; Michael T Beste; Zainab Lasisi; Sonika Reddy; Karen W Jeng; Chia-Hung Chen; Jongyoon Han; Keith Isaacson; Linda G Griffith; Douglas A Lauffenburger
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.